Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Growth Inhibition of Human Uterine Leiomyoma Cells Using Haeohyul-tang

하어혈탕(下瘀血湯)이 1차배양된 인체자궁근종세포(人體子宮筋腫細胞)에 미치는 영향

  • Kim, Han-Kyun (College of Oriental Medicine, Daegu Haany University) ;
  • Zhao, Rong-Jie (College of Oriental Medicine, Daegu Haany University, College of Medicine, Yanbian University) ;
  • Jo, Mi-Jeong (College of Oriental Medicine, Daegu Haany University) ;
  • Choi, Sun-Mi (Korea Institute of Oriental Medicine) ;
  • Park, Sook-Jahr (College of Oriental Medicine, Daegu Haany University, Development Team for The New Drug of Oriental Medicine (BK21 Program) Daegu Haany University) ;
  • Kim, Mi-Ryeo (College of Oriental Medicine, Daegu Haany University, Development Team for The New Drug of Oriental Medicine (BK21 Program) Daegu Haany University) ;
  • Kwon, Young-Kyu (College of Oriental Medicine, Daegu Haany University, Development Team for The New Drug of Oriental Medicine (BK21 Program) Daegu Haany University) ;
  • Kim, Sang-Chan (College of Oriental Medicine, Daegu Haany University, Development Team for The New Drug of Oriental Medicine (BK21 Program) Daegu Haany University)
  • 김한균 (대구한의대학교 한의과대학) ;
  • 조용걸 (대구한의대학교 한의과대학, 연변대학교 의과대학) ;
  • 조미정 (대구한의대학교 한의과대학) ;
  • 최선미 (한국한의학연구원) ;
  • 박숙자 (대구한의대학교 한의과대학, 한방신약개발연구팀(BK21)) ;
  • 김미려 (대구한의대학교 한의과대학, 한방신약개발연구팀(BK21)) ;
  • 권영규 (대구한의대학교 한의과대학, 한방신약개발연구팀(BK21)) ;
  • 김상찬 (대구한의대학교 한의과대학, 한방신약개발연구팀(BK21))
  • Published : 2007.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Uterine leiomyoma is the most common tumor in the female genital tract. Although the tumor is benign, it is a matter of paramount importance since it often causes profuse menstrual bleeding, pressure symptoms and infertility. Nevertheless, the etiology and pathophysiology of this abnormality remain poorly understood. The traditional definitive treatment for uterine leiomyomas is hysterectomy and, even today, symptomatic leiomyomas are the leading cause of hysterectomy in Korea. Clearly, the development of a safe, effective, and nonsurgical method of treatment for leiomyoma would be of great benefit to many women. This study demonstrated growth inhibition of uterine leiomyoma cells using Haeohyultang (HT). When human leiomyoma cells were treated with Haeohyultang, cells showed dose-dependent growth inhibitory effect. Cell growth was inhibited by over 40% as determined by both cell counts and MTS assay. Reduction of cellular viability as a consequence of exposure to Haeohyultang resulted from induction of apoptosis, as assessed by DNA fragmentation, PARP cleavage, caspase 9 and caspase 3 assay. Flow cytometry analysis with uterine leiomyoma cells demonstrated sub G1 cell cycle arrest after treatment with drug Haeohyultang. But, the expression levels of p27 and p21 were not changed in Haeohyultang treated cells compared with control. However, the expression levels of clAP1 were reduced by Haeohyultang compared with control. This reduction of clAP1 data means activation of the caspase family, and then induction of PARP cleavage and apoptosis. These results suggest that Haeohyultang may be potential therapeutic approach in the clinical management of uterine leiomyoma.

Keywords

References

  1. Buttram, V.C., Reiter, R.C. Uterine leiomyomata : Etiology, symptomatology, and management. Fertil. Steril. 36: 433-445, 1981 https://doi.org/10.1016/S0015-0282(16)45789-4
  2. Gambone, J.C., Reiter, R.C., Lench, J.B., Moore, J.G. The impact of a quality assurance process on the frequency and confirmation rate of hysterectomy. Am. J. Obstet. Gynecol. 63:545-550, 1990
  3. 신영우, 변영진, 나영호, 김창학, 권순욱. 복식 전자궁 적출술에 관한 임상 통계적 고찰. 대한산부회지 28:90, 1985
  4. 裵恩敬, 李京燮, 宋炳基. 子宮筋腫의 韓醫學的 接近. 大韓韓方婦人科學會誌 7(1):79-86, 1994
  5. 梁秀烈, 李京燮, 宋炳基. 子宮筋腫의 治驗1例. 大韓韓醫學會誌 11(1):33-38, 1990
  6. 이종학. 자궁근종에 대한 임상적 및 병리학적 연구. 대한산부인과학회지 30:213-222, 1987
  7. 王曉萍. 婦産科病症治精要. 北京, 科學技述文獻出版社. pp 208-236, 1999
  8. 백원민. 자궁근종의 임상적 고찰. 대한산부인과학회지 26: 1047-1054, 1983
  9. 송계승. 자궁근종의 임상통계학적 관찰. 대한산부인과학회지 30:981-988, 1987
  10. Miller, N.F., Ludovici, P.P. Origin and development of uterine fibroids. Am. J. Obstet. Gynecol. 70:720, 1985
  11. Lipshultz, A. Expeimental fibroids and the antifibromatogenic action of steroid hormones. JAMA 120:173, 1984
  12. 梁秀烈, 李京燮, 宋炳基. 癥瘕의 東西醫學的 考察. 大韓韓醫學會誌 7(1):84-88, 1986
  13. 梁秀烈, 李京燮, 宋炳基. 癥瘕患者에 對한 臨床的 考察. 大韓韓方婦人科學會誌 4(1):23-27, 1991
  14. 宋炳基. 漢方婦人科學. 서울, 杏林出版社. pp 249-256, 1980
  15. 李京燮, 宋炳基. 癥瘕 狀態에 關한 文獻的 考察. 서울, 東洋醫學硏究室. pp 46-52, 1980
  16. 문구, 조성각. 積聚處方에 對한 文獻的 考察. 大韓韓方腫瘍學會誌 1(2):315-329, 1996
  17. 王肯堂. 六科準繩. 서울, 大星文化社. pp 252-268, 1992
  18. 宋炳基. 邪客子門의 證治體系에 關한 考察. 서울, 醫林. pp 150, 1982
  19. 宋炳基. 韓方婦人科學. 서울, 杏林出版. pp 251, 254-256, 1992
  20. 金鍾桓. 子宮筋腫의 治療法에 關한 韓醫學的 考察. 大韓韓方婦人科學會誌 11(1):209-227, 1998
  21. 申鎭湜. 比較醫學的 側面에서 본 癥瘕의 疾病에 關한 文獻的 考察. 東醫病理學會誌. 1:67-70, 1984
  22. 鄭奉天. 子宮筋種의 治驗. 大田大學校論文集. 1(1):15-33, 1992
  23. 한의부인과학 편찬위원회. 韓醫婦人科學. 서울, 도서출판 정담. pp 303-313, 2002
  24. 許浚. 原本 東醫寶鑑. 서울, 南山堂. pp 490, 1991
  25. 張機. 金匱要略自學輔導. 서울, 中醫古籍出版社. pp 172, 173, 1988
  26. 萬全. 萬氏婦人科. 湖北, 湖北人民出版社. pp 10, 1983
  27. 李克光, 金匱要略譯釋. 上海, 上海科學技術出版社. pp 641, 1993
  28. 金眞喜, 白承嬉. 桂枝茯苓丸이 子宮筋腫細胞의 成長억제와 MAP Kinase 活性에 미치는 影響. 大韓韓方婦人科學會誌 14(2):85-101, 2001
  29. 白承嬉, 李京燮, 宋炳基. 七製香附丸이 子宮細胞株이 成長과 排卵 및 着床前胚發生에 미치는 影響. 大韓韓方婦人科學會誌 13(1):186-218, 2000
  30. Stewart, E.A., Faur, A. The future of fibroid therapy. Contemp. Obstet. Gynecol. 45:26-35, 2000
  31. Brandon, D.D., Erickson, T.E., Keenan, E.J., Strawn, E.Y., Novy, M.J., Burry, K.A., Warner, C., Clinton, G.M. Estrogen receptor gene expression in human uterine leiomyomata. J. Clinic. Endocrinol. Metab. 80:1876-1881, 1995 https://doi.org/10.1210/jc.80.6.1876
  32. West, C.P., Lumsden, M.A., Lawson, S., Williamson, J., Baird, D.T. Shirinkage of uterine fibroids during therapy with goserelin(Zoradex) : a lutenizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil. Steril. 48:45-51, 1987
  33. Murphy, A.A., Morales, A.J., Kettel, L.M., Yen, S.S. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil. Steril 64(1):187-190, 1995
  34. Lee, B.S., Marolin, S.B., Nowa, R.A. Pirfenidone: A novel pharmacological agent that inhibit leiomyoma cell proliferation and collagen production. J. Clinic. Endocrinol. Metab. 83:219-223, 1998 https://doi.org/10.1210/jc.83.1.219
  35. Nowak, R.A. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors. Environ. Health Perspect. 108 Suppl 5:849-853, 2000 https://doi.org/10.2307/3454318
  36. Lee, B.S., Nowak, R.A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta3(TGF beta 3) and altered responses to the atiproliferative effects of TGF beta. J. Clinic. Endocrinol. Metab. 86:913-920, 2001 https://doi.org/10.1210/jc.86.2.913
  37. Sumitani, H., Shozu, M., Segawa, T., Murakami, K., Yang, H.J., Shimada, K., Inoue, M. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 141:3852-3861, 2000 https://doi.org/10.1210/en.141.10.3852
  38. Matuo, H., Maruo, T., Samoto, T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J. Clinic. Endocrinol. Metab. 82:293-299, 1997 https://doi.org/10.1210/jc.82.1.293
  39. Arici, A., Sozen, I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil. Steril. 73:1006-1011, 2000 https://doi.org/10.1016/S0015-0282(00)00418-0
  40. Klagsbrun, M., Dluz, S. Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. Induction of mRNA levels and secretion of active mitogen. J. Biol. Chem. 268: 18330-18334, 1993
  41. Strawn, Jr E.Y., Novy, M.J., Burry, K.A., Bethea, C.L. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am. J. Obstet. Gynecol. 172:1837-1844, 1995 https://doi.org/10.1016/0002-9378(95)91420-X
  42. Niu, H., Simari, R.D., Zimmerman, E.M., et al. Nonviral vector-mediated thymidine kinase gene transfer and ganciclover treatment in leiomyoma cells. Obstet. Gynecol. 91:735-740, 1998 https://doi.org/10.1016/S0029-7844(98)00014-3
  43. aek, W., Kim, D., Jung, N., Cha, S., Bae, I., Cho, C., et al. Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. Am. J. Obstet. Gynecol. 188: 634-639, 2003 https://doi.org/10.1067/mob.2003.140
  44. 대한산부인과학회. 부인과학(3판). 서울, 도서출판칼빈서적. pp 473-488, 1991
  45. 華陀. 中藏經. 서울, 成輔社. pp 4, 13, 1978
  46. 巢元方 著. 丁光迪 主編. 諸病源候論校註(下). 北京, 人民衛生出版社. pp 1107-1110, 1992.
  47. 吳謙 等編. 醫宗金鑑下冊. 北京, 人民衛生出版社. p 38, 1982
  48. 許浚. 東醫寶鑑. 서울, 南山堂. pp 487, 490, 491, 1975
  49. 王氷 註. 黃帝內經. 서울, 高文社. pp 75, 80, 112, 123, 147, 172, 281, 296, 353, 1971
  50. 孫思邈. 備急千金要方. 北京, 人民衛生出版社. pp 59-62, 66, 211-215, 1982
  51. 전국한의과대학 본초학교수 공편저. 본초학. 서울, 영림사. pp 242-243, 423-424, 430-431, 1991
  52. 李尙仁, 金東傑, 李暎鍾, 盧昇鉉, 朱榮丞. 方劑學. 서울, 永林社. pp 245-246, 1990